The study for surgical outcome of trabeculectomy for neovascular glaucomatous patients who received an additional bevacizumab treatment after the surgery.

UMIN ID: UMIN000000895

Registered date:19/11/2007

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Patients with neovascular glaucoma
• Date of first enrollment: 2007/11/01
• Target sample size: 40
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Patients are treated with an intravitreal injection of 1.25 mg bevacizumab (avastin) within 5 days before trabeculectomy, then treated with trabeculectomy. Then, they are treated with an intravitreal injection of 1.25 mg bevacizumab (Avastin), on 2 weeks after trabeculectomy.
Patients are treated with an intravitreal injection of 1.25 mg bevacizumab (avastin) within 5 days before trabeculectomy, then treated with trabeculectomy. Then, they are not treated with bevacizumab (Avastin).

Outcome(s)

• Primary Outcome: Intraocular pressure levels after an additional treatment of bevacizumab following trabeculectomy.
• Secondary Outcome: The size of filtrating bleb. The inflammation in the anterior chamber The concentrations of cytokines in the anterior chamber.

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Patients who have been previously treated with trabeculectomy. Patients who had been treated with bevacizumab within recent 2 months.

Related Information

• Primary Sponsor: Kumamoto University
• Source(s) of Monetary Support: None